Company intelligence / Profile preview

Berlin Heals

Ownership: Private
Employees: ~23
Development stage: Other

Overview

Berlin Heals’ C-MIC device has shown significant and rapid improvements in heart function and quality of life for patients with advanced heart failure. First-in-human pilot studies demonstrated strong efficacy and safety. The pivotal European CE trial was recommended to end early due to clear benefit; long-term data show sustained improvement even after the device was turned off. The company expects CE approval by late 2025 and has received FDA Breakthrough Device Designation for its US program.

Therapeutic areas: Cardiovascular
Modalities: DeviceElectroceutical therapy (implantable microcurrent device)Non-pharmacological therapy
Industry: Therapeutic Medical Devices

Partnerships

Collaboration with Medical University of Vienna for preclinical research

Beyond the preview

Go deeper on Berlin Heals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Berlin Heals.

Explore the full profile